Camobucol

Camobucol (AGIX-4207) is an orally active, small molecule phenolic antioxidant and anti-inflammatory compound developed by AtheroGenics. It is a derivative of probucol, modified with an acetic acid side chain to improve its pharmacological profile. Camobucol functions by selectively inhibiting the expression of redox-sensitive inflammatory genes, most notably Vascular Cell Adhesion Molecule-1 (VCAM-1) and Monocyte Chemoattractant Protein-1 (MCP-1). Its mechanism of action is distinct in that it operates independently of the NF-kappaB pathway, a common target for other anti-inflammatory agents. In addition to gene inhibition, it suppresses the production of several pro-inflammatory cytokines, including TNF-alpha, IL-1beta, IL-6, and IL-8, and acts as a scavenger of reactive oxygen species (ROS). The drug was primarily investigated for the treatment of rheumatoid arthritis and was also explored for potential applications in cardiovascular disease, reaching Phase 2 clinical trials before development was halted following the developer's financial restructuring.

Other names

2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acidAtheroGenics-4207AtheroGenics4207AtheroGenics 4207